May 11, 2026 · Form 4 insider transaction
GC Corp. bought 1,085,069 shares of Artiva Biotherapeutics, Inc. at $11.52 per share, a transaction worth $12.50M. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 17 days after the transaction.
GC Corp., a public Korean holdings company, is ultimately controlled by its board of directors. As of March 26, 2026, the board consists of: Mr. Yong-Jun Huh, Huh Il-Sup, Park Yong-Tae, Kang Joonho, and Lee Choonwoo. Each of these individual directors of GC Corp. may be deemed to share voting and investment power over the shares held by GC Corp. and each disclaims beneficial ownership of all shares held by GC Corp., except to the extent of any pecuniary interest therein.